Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 12,093

Document Document Title
WO/2024/041573A1
This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D or other KRAS mutants, and their uses.  
WO/2024/043741A1
The present invention relates to a novel compound for the inhibition of autotaxin, a stereoisomer thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing s...  
WO/2024/040190A1
Provided are compounds of Formula (I). Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formu...  
WO/2024/039886A1
Benzazepine derivatives of Formula (I), compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with ce...  
WO/2024/040131A1
This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a), (I-aa), (I-b), (I-bb), (I-c), (I-cc), (I-d), (I-dd), (I-e), (I-ee), (I-f), (I-g), or (I-h)), Formula (II) (e.g., (II-c), (II-cc), (II-d), (II-dd),...  
WO/2024/037616A1
The present application relates to a compound containing cyclohexyl, in particular to a compound of formula (I-AA), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition c...  
WO/2024/040109A2
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.  
WO/2024/032755A1
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2024/033277A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of usin...  
WO/2024/032747A1
The present application relates to tricyclic compounds and medical use thereof. The structure is represented by formula (I). Specifically, the present application further relates to a preparation method for the compounds, a pharmaceutica...  
WO/2024/032704A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating the activity of KRAS G12D and/or G12V.  
WO/2024/033454A1
The present invention relates to compounds of formula (I), wherein A1 to A7and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.  
WO/2024/032702A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.  
WO/2024/032703A1
Provided herein are compounds having the following structure: wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of KRAS G12D and/or G12V.  
WO/2024/032776A1
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2024/032390A1
Provided are a macrocyclic triazole compound represented by formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt, or a ...  
WO/2024/027631A1
The present disclosure relates to a crystal form of a fused tricyclic derivative and a preparation method, and specifically relates to a crystal form of a compound (3S,4R)-4-((5-chloro-4-((S)-8-fluoro-2-(2-hydroxypropane-2-y l)-3-methyl-...  
WO/2024/031088A1
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...  
WO/2024/027814A1
Disclosed are a compound as represented by formula (I) having a KRas G12D inhibitory effect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the use thereof in the preparation of a drug for KRas G12D-related...  
WO/2024/025817A1
Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrid o[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use t...  
WO/2024/023284A1
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...  
WO/2024/022167A1
The present invention provides a novel camptothecin derivative compound, a pharmaceutically acceptable salt, a stereoisomer, or a prodrug thereof, and a method for preparing same and use thereof. The compound has a structure represented ...  
WO/2024/022435A1
Disclosed are a crystal form of a 5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine compound, a preparation method therefor, and the use of the crystal form in the preparation of a medicament for treating relevant diseases. Specifically di...  
WO/2024/022444A1
The present disclosure relates to a fused ring compound, a preparation method therefor and a medicinal application thereof. Specifically, the present disclosure relates to a fused ring compound represented by general formula (IN), a prep...  
WO/2024/022266A1
The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...  
WO/2024/022286A1
The present invention relates to a macrocyclic EGFR inhibitor and a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an EGFR inhibitor having a structure of formula (I), a ph...  
WO/2024/020517A1
Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...  
WO/2024/020380A1
Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...  
WO/2024/017392A1
Disclosed in the present invention are a pyrimidine ring compound, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof. The pyrimidine ring compound is a compound as represented by formula (I) or formula (II)...  
WO/2024/016986A1
The present invention relates to a macrocyclic inhibitor, a composition and a use thereof. In particular, the present invention relates to a compound as shown in formula (I), a pharmaceutical composition comprising the compound of the pr...  
WO/2024/017380A1
Disclosed in the present invention are a tricyclic-containing macrocyclic compound and a use thereof, and particularly disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.  
WO/2024/017358A1
The present invention relates to a macrocyclic inhibitor, a composition, and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a pharmaceutical composition containing said compound, and...  
WO/2024/020068A1
Disclosed are bacterial topoisomerase inhibitors with antibacterial activity, including against fluoroquinolone-resistant Staphylococcus aureus, comprising structural domains: a) a left-hand side (LHS) usually comprising a fused bicyclic...  
WO/2024/017251A1
The present disclosure relates to a macrocycle for inhibiting and inducing EGFR degradation and a preparation method for and a use of the macrocycle. Specifically, the present disclosure relates to a macrocycle as shown in general formul...  
WO/2024/017258A1
Disclosed in the present invention are a multi-target small molecule inhibitor, a pharmaceutical composition containing same, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I)....  
WO/2024/017857A1
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.  
WO/2024/015340A1
Described herein are compounds or conjugates of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading ce...  
WO/2024/015346A1
Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for ce...  
WO/2024/015497A1
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...  
WO/2024/015406A1
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).  
WO/2024/011294A1
The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...  
WO/2024/015409A1
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).  
WO/2024/015408A1
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).  
WO/2024/015412A1
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).  
WO/2024/008113A1
The present invention relates to a formamide-substituted heterotricyclic derivative represented by formula (I), a method for preparing same, and use thereof. The present invention further relates to a pharmaceutical composition comprisin...  
WO/2024/008610A1
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.  
WO/2024/010336A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2024/011155A1
Described herein are oxazole TRPML1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.  
WO/2024/007997A1
Disclosed in the present invention are a crystal form of a pyridone polycyclic derivative and a preparation method therefor, and particularly a crystal form of a compound as represented by formula (I) and a preparation method therefor.  
WO/2024/006916A1
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.  

Matches 101 - 150 out of 12,093